SCHEMBL6990724

SCHEMBL6990724

COc1ccc2c(C)noc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.49
KDM4E B2RXH2 7/20 0.47
ALDH1A1 P00352 6/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 2/20 0.47
CHRNA7 P36544 2/20 0.45
HTR3A P46098 2/20 0.45
MAPT P10636 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
POLB P06746 2/20 0.45
STAT1 P42224 1/20 0.45
GAA P10253 1/20 0.44
MAOB P27338 4/20 0.43
MAOA P21397 1/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.42
TP53 P04637 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6990506 0.85 BRD4 (0.49) BRD4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL8140185 0.81 CHRNA7 (0.45) KDM4EALDH1A1HPGDHSD17B10CHRNA7
SCHEMBL1536638 0.80 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10CHRNA7
SCHEMBL6952286 0.80 CLK1 (0.50) KDM4EALDH1A1HPGDHSD17B10CHRNA7
SCHEMBL12463919 0.80 CHRNA7 (0.44) KDM4EALDH1A1HPGDHSD17B10CHRNA7
SCHEMBL1562381 0.80 NQO1 (0.44) KDM4EALDH1A1HPGDHSD17B10CHRNA7
SCHEMBL2201085 0.78 CA12 (0.49) BRD4
SCHEMBL6374522 0.78 ESR1 (0.59) KDM4EALDH1A1HPGDHSD17B10CHRNA7
SCHEMBL4399692 0.76 CHRNB2 (0.45) BRD4KDM4EALDH1A1HPGDCHRNA7
SCHEMBL26083923 0.76 ACHE (0.47) KDM4EALDH1A1HPGDHSD17B10CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 US disclosed
WO-2025068943-A1 KAT6 INHIBITORS BEIGENE SWITZERLAND GMBH (CH) 2025-04-03 WO disclosed
EP-3795563-B1 INDOLINE ANALOGS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2024-07-17 EP disclosed
EP-3795563-B1 INDOLINE ANALOGS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2024-07-17 EP disclosed
CN-109219594-B Indoline analogue and application thereof 英克特诺治疗公司 2022-10-11 CN disclosed
EP-3795563-A1 INDOLINE ANALOGS AND USES THEREOF Oncternal Therapeutics, Inc. (US) 2021-03-24 EP disclosed
EP-3795563-A1 INDOLINE ANALOGS AND USES THEREOF Oncternal Therapeutics, Inc. (US) 2021-03-24 EP disclosed
US-10711008-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2020-07-14 US disclosed
US-10711008-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2020-07-14 US disclosed
EP-3436434-B1 INDOLINE ANALOGS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2020-07-08 EP disclosed
US-6326382-B1 CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE EISAI CO., LTD (JP) 2001-12-04 US disclosed
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists HOWARD HARRY R (US) 2001-09-20 US disclosed
US-5854262-A Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. (US) 1998-12-29 US disclosed
US-5750542-A Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors PFIZER (US) 1998-05-12 US disclosed
EP-0806423-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists PFIZER INC. (US) 1997-11-12 EP disclosed
US-5538984-A Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors PFIZER INC. (US) 1996-07-23 US disclosed
EP-0675886-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1995-10-11 EP disclosed
EP-0646115-A1 HETEROCYCLIC-CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 1995-04-05 EP disclosed
WO-1994013663-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO disclosed
WO-1992017475-A1 HETEROCYCLIC-CYCLIC AMINE DERIVATIVES PFIZER INC. (US) 1992-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists NPY1R, OPRK1, OPRL1 BRD4 1739/4885KDM4E 1271/4885ALDH1A1 856/4885
US-10711008-B2 Indoline analogs and uses thereof FLI1, EWSR1, IKZF1 BRD4 189/4885KDM4E 1182/4885ALDH1A1 2456/4885
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 BRD4 303/4885KDM4E 948/4885ALDH1A1 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.